Clinical Trial Update: Letermovir Prophylaxis for Cytomegalovirus (CMV) in Patients With Graft-versus-host Disease [Phase 2]

View source ↗

Summary

Phase 2 trial update investigating letermovir prophylaxis for CMV in patients with graft-versus-host disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cytomegalovirus Infection
• Graft-versus-host Disease

Drugs mentioned

• Letermovir (letermovir)

Snippet

Sponsor: Rabin Medical Center | Conditions: Graft-versus-host-disease, CMV | Phase 2 | Status: UNKNOWN